-
Covid 19 Millions Suffer but is it a Blessing in Disguise for PF Patients ?
Research into PF & IPF is restricted by the lack of Funding and Resources due to the relative low numbers of sufferers and therefore classified as a Rare Disease. Also when treatments are developed they tend to be very expensive and can cause patient distress. However with millions around the world now suffering from Covid 19 it is predicted that 2% of these patients will have suffered a degree of fibrotic lung scarring. This produces a huge population of PF patients which will drive the research and treatments for this devastating disease.
A new potential PF treatment was reported in the UK news today for the treatment Covid 19 PF patients at London’s Guy’s & St Thomas’s Hospital. They simply collect a bag of blood from the patient then spin it in the lab to separate a type of white blood called a Macrophage. This is then infused back into the patient to dissolve the lung scarring ! It states 5 patients to date have been treated and a larger trial is planned. Sounds so simple and too good to be true. Has this method ever been tried in the USA .Even if this trial does not deliver the expected results the large population of Covid PF suffers will drive the research forward in years to come giving us the spin off benefits
Log in to reply.